Publications
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)2012 | First Faculty of Medicine
- Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathwayPublication without faculty affiliation
- True monosomy of chromosome 5 is presumably not an isolated cytogenetic entity in MDSPublication without faculty affiliation
- Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1)Publication without faculty affiliation
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
Loading network view...
